関連する実験動画

Updated: Jun 26, 2025

Control of Eating Behavior Using a Novel Feedback System
04:48

Control of Eating Behavior Using a Novel Feedback System

Published on: May 8, 2018

11.0K

肥満に対する実験薬は,体重を減らすためのダブルパンチです

Asher Mullard

    Nature
    |May 15, 2024
    PubMed
    まとめ

    No abstract available in PubMed .

    キーワード:
    化学について薬物の発見肥満

    さらに関連する動画

    Self-Administration of Drugs in Mouse Models of Feeding and Obesity
    03:37

    Self-Administration of Drugs in Mouse Models of Feeding and Obesity

    Published on: June 8, 2021

    4.5K
    A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
    06:28

    A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

    Published on: April 28, 2023

    827

    関連する実験動画

    Last Updated: Jun 26, 2025

    Control of Eating Behavior Using a Novel Feedback System
    04:48

    Control of Eating Behavior Using a Novel Feedback System

    Published on: May 8, 2018

    11.0K
    Self-Administration of Drugs in Mouse Models of Feeding and Obesity
    03:37

    Self-Administration of Drugs in Mouse Models of Feeding and Obesity

    Published on: June 8, 2021

    4.5K
    A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
    06:28

    A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

    Published on: April 28, 2023

    827

    関連する概念動画

    Glucagon-like Receptor Agonists01:24

    Glucagon-like Receptor Agonists

    318
    Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
    GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
    318
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    JoVEについて
    概要リーダーシップブログJoVEヘルプセンター
    著者向け
    出版プロセス編集委員会範囲と方針査読よくある質問投稿
    図書館員向け
    推薦の声購読アクセスリソース図書館諮問委員会よくある質問
    研究
    JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
    教育
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
    利用規約
    プライバシーポリシー
    ポリシー
    Jove
    Visualize
    お問い合わせ